Press Releases

2022

December 07, 2022
KSQ Therapeutics Announces First Patient Dosed in Combination Portion of the Ongoing Phase 1 Study of KSQ-4279, A First-In-Class USP1 Inhibitor, In Patients with Advanced Solid Tumors

September 23, 2022
KSQ Therapeutics Announces Leadership and Board Additions

March 22, 2022
KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting

2021

November 13, 2021
SITC Poster Presentation: "KSQ-004: Unbiased Pair-wise Discovery of SOCS1 and Regnase-1 as the Top CRISPR/Cas9 Dual-edit Combination Enhancing In vivo TIL Potency Against Solid Tumors"

November 13, 2021
SITC Poster Presentation: "Development of KSQ-001, an Engineered TIL (eTIL™) Therapy for Solid Tumors through CRISPR/Cas9-mediated Inactivation of SOCS1"

September 22, 2021
KSQ Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 14, 2021
KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

May 13, 2021
KSQ Therapeutics Appoints Chris Heberlig as Chief Financial Officer

March 10, 2021
KSQ Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

February 01, 2021
KSQ Therapeutics Strengthens Leadership Team with Promotion of Micah Benson, Ph.D., to Senior Vice President, Head of Immunobiology and Andrew Wylie, Ph.D., to Senior Vice President, Head of Oncology

January 25, 2021
KSQ® Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer

January 13, 2021
KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies

2020

October 24, 2020
KSQ® Therapeutics Presents First Preclinical Data for KSQ-4279, a Novel USP1 Inhibitor, for the Treatment of BRCA-Deficient Cancers

September 24, 2020
KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

June 22, 2020
AACR Poster Presentation: "KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapy for Solid Tumors

May 12, 2020
ASGCT Poster Presentation: "Systematic identification of potent guide RNAs with minimal off-target activity for the CRISPR/Cas9 engineering of KSQ-001, and engineered Tumor Infiltrating Lymphocyte (eTIL™)"

February 09, 2020
KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors

2019

December 04, 2019
MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs

December 03, 2019
KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs

November 12, 2019
KSQ Therapeutics Enhances Board of Directors with Two Appointments

November 09, 2019
SITC Poster Presentation: "An Immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets"

October 29, 2019
EORTC Poster Presentation: "Comprehensive Identification of Novel Therapeutic Targets for Treatment of PD-1 Resistant Solid Tumors via a Genome-Scale CRISPR/cas9 in vivo T-cell Screen"

October 28, 2019
KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine

October 15, 2019
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

2018

September 28, 2018
KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD 1 Resistant Solid Tumors

September 25, 2018
KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors

2017

October 02, 2017
KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug Development